Navigation Links
UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
Date:11/1/2007

onse to beta blocker therapy for hypertension."

In this 12-week double-blind trial, 300 African-American patients with stage I-II hypertension were randomly assigned to receive once-daily placebo or nebivolol at a 2.5, 5, 10, 20, or 40 mg dose. Among the 259 patients who completed the 12-week therapy, by comparison to placebo treatment, nebivolol significantly reduced sitting diastolic blood pressure at all daily doses greater than or equal to 5 mg and sitting systolic blood pressure at all daily doses greater than or equal to 10 mg with a low rate of side effects.

"This data further supports nebivolol's ability to lower blood pressure in a broad range of patients, including patients that are typically hard to treat with beta blockers such as African Americans," says Neil Shusterman, MD, Senior Vice President, Clinical Development of Forest Research Institute. "In addition to these blood pressure reductions, the low incidence of typical beta blocker side effects seen with nebivolol will make it a welcome addition to the existing treatment paradigm."

About Hypertension

Hypertension, also known as high blood pressure, affects approximately 72 million people in the U.S. and 65 percent of patients diagnosed with hypertension have not reduced their blood pressure to an acceptable range. If left untreated, hypertension can eventually damage important organs such as the heart, brain, eyes or kidneys. High blood pressure greatly increases the risk of certain health problems such as stroke, heart attack, and kidney failure.

About Nebivolol

Nebivolol is a selective beta 1-blocker with vasodilating properties and is already approved and successfully marketed for the treatment of hypertension in more than 50 countries outside of North America.

About Forest Laboratories and Its Products

Forest Laboratories is a US-based pharmaceutical company dedicated to identifying, developing, and delivering products that make a positive differe
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine technology :

1. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
2. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
3. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
4. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
8. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
9. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
10. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
11. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2008)... Awareness and Bring Hope to Millions,of Children ...e/ -- 133 million children,across the globe are wi...disaster, civil war, and disease. SOS Children,s V...ek by calling attention to the needs of orphans,wo... to:, http://www.prnewswire.com/mnr/soschildrens...
(Date:10/9/2008)...s and Marketing Efforts to Accelerate ... PARK, Calif., Oct. 9 /- Evalve, Inc.... percutaneous repair of cardiac valves,has expand... appointment of,Sean Cleary as senior vice preside...ardson, as vice president of sales., "The additio...
(Date:10/9/2008)...titute, Navigenics, Affymetrix and,Microsoft team ... /- A consortium of health care,tech...a first-of-its-kind,research study to assess the b...ople who choose to receive such screenings to iden...iseases., Sponsored by Scripps Translational Scie...
(Date:10/8/2008)...re-USNewswire/ -- The facts are,overwhelming. Ever...b-Saharan Africa. More than 35,000,000 women, chil...ied of AIDS. The Foundation for Hospices,in Sub-Sa...eir families,find compassion and relief from suffe...ring initiative links African hospices and palliat...
Breaking Medicine Technology:Photos: SOS Children's Villages Observes World Orphan Week, October 5-11, 2008 2Evalve Expands Executive Leadership Team 2Evalve Expands Executive Leadership Team 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 4Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 5In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 1Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 2Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 3Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 4Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 5Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 6Overuse of Opioids Barbiturates Boosts Chronic Migraine Risk 17140 1Migraines Frequency Influences Heart Attack Stroke Risk 17138 1Migraines Frequency Influences Heart Attack Stroke Risk 17138 2Migraines Frequency Influences Heart Attack Stroke Risk 17138 3Parents stricter with older kids to set example 3A game theory study 17136 1Parents stricter with older kids to set example 3A game theory study 17136 2
...h 20, 2007 /PRNewswire-FirstCall/ --,Alfacell Corp...l to,act as a potent payload in antibody conjugate...ion of the Handbook of Therapeutic,Antibodies. , I... Susanna,Rybak, Ph.D. summarizes preclinical resea... ONCONASE improves in a number of tumor,models, in...
...Enzyme Levels in Two Most Common Mutations, CRANBU...erapeutics, a biopharmaceutical company developing...al chaperones for the,treatment of a range of huma...resent the results of preclinical studies of,Plice...disease at,the of Medical Genetics (ACMG) annual m...
Other Medicine Technology:Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...reatment could help prevent future blood clots in ...mboembolism (VTE) affects approximately 2 million ...osis (blood clots common in the thigh and back) an...on in the lung). Despite progress in diagnosis and...
...ion for some patients with large liver tumors. The... //before using lasers to heat and destroy the tum...proves the overall survival of the patients. Radio...nduced thermotherapy (LITT) to heat tumors. The pr...
...on that can be fatal. It is defined as an obstruct... a blood clot, //which blocks a coronary artery. W...onary embolism, a new study shows a new treatment ...inister to patients than the current treatment. Ac...
...f the American Society of Therapeutic Radiology an...beam radiation may be what it takes to relieve pai...d to the bone. More than 160 hospitals and univers...were involved in a study of about 900 men and wome...
Other Medicine News:Health News:Extended Therapy for Blood Clots 2Health News:New Liver Tumor Treatment 2
...w XCD-SX910CR digital camera incorporates a Progre...excellent sensitivity (1280 (H) x 960 (V) SXGA. Wh...ask (commonly called a "Bayer filter") and outputs... converted to a color image on the computer. The c...
...661 is a monochrome " 1.3 Megapixel FireWire camer...s. Desgined to simplify real-time uncompressed vi...A661 provides uncompromising video and digital sti...-A661 is ideal for industrial inspection tasks inv...
...h acclaimed GT-CAPTURE digital camera photomicrogr...ers microscope such as Olympus, Leica, Nikon, and ...sferring images over the Internet easy and fast. F...ormance-proven Nikkor lens. The system records pho...
...0 is a superb stand-alone digital camera with netw...es from local or remote locations. Image acquisiti...amera operates independently or attaches directly ...o capture and transfer images. Sharing images in r...
Medicine Products: